Jun 2026 (Q2 FY26) — Aug 6, 2026
Collegium Q2 FY26 — Strong ADHD Growth and Astaris Integration
Read the full callCollegium (COLL) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Collegium earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 200 | +6.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 1.9 | −16.8 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -15.1 | −225.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$23.01 −0.78% · −$0.18
Performance −32.2% 1Y
1Y: $33.94 on 17 Oct 2025 → $23.01. High $49.84 (26 Dec 2025), low $21.53 (13 Oct 2026).
- Previous close
- $23.19
- 52-week range
- $21.53 – $49.84
- One year
- −33.97%
Overview
- Symbol
- COLL
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Collegium earnings calls (COLL)
Financials
What the filings say
Net profit, year on year: −226% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 159 | 182 | 178 | 188 | 209 | 205 | 194 | 200 |
| Operating profit | 35 | 38 | 22 | 35 | 62 | 61 | 31 | 4 |
| Operating margin | 21.9% | 20.9% | 12.2% | 18.7% | 29.7% | 29.6% | 16.0% | 1.9% |
| Interest | 18 | 23 | 21 | 20 | 22 | 19 | 16 | 20 |
| Profit before tax | 16 | 17 | 3 | 17 | 43 | 29 | 19 | -14 |
| Tax rate | 40.1% | 27.4% | 22.6% | 29.6% | 27.5% | 41.6% | 22.6% | −11.2% |
| Net profit | 9 | 13 | 2 | 12 | 32 | 17 | 14 | -15 |
| EPS ($ per share) | 0.29 | 0.39 | 0.08 | 0.38 | 1 | 0.54 | 0.45 | -0.46 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -337 | -360 | -333 | -256 | -281 | -233 | -164 | -101 |
| Total liabilities | 200 | 219 | 458 | 489 | 979 | 948 | 1,435 | 1,355 |
| Fixed assets | 9 | 12 | 19 | 19 | 20 | 16 | 14 | 12 |
| Investments | — | — | — | — | 0 | 72 | 92 | 155 |
| Total assets | 291 | 306 | 644 | 692 | 1,174 | 1,143 | 1,664 | 1,657 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 169 | 28 | 94 | 104 | 124 | 275 | 205 | 329 |
| Cash from investing | -24 | -6 | -374 | -2 | -574 | -71 | -288 | -64 |
| Cash from financing | -117 | 2 | 286 | -89 | 437 | -140 | -61 | -110 |
| Capital expenditure | -5 | -6 | -6 | -2 | -2 | -0 | -2 | -2 |
| Free cash flow | 164 | 21 | 88 | 102 | 123 | 274 | 203 | 328 |
Insider filings
47 filings between Nov 6, 2025 and Jun 8, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$7.25M
14 sales by 8 insiders
57% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 17
- Award — granted as compensation
- 6
- Option exercise — converted options into shares
- 10
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Dreyer Scott | — | $2.87M | Mar 3, 2026 |
| Fallon John A. | — | $1.65M | Nov 12, 2025 |
| Tupper Colleen | — | $1.22M | Nov 6, 2025 |
| Dieter David | — | $716.2K | Mar 18, 2026 |
| BOHLIN GAREN G | — | $323.5K | May 11, 2026 |
| Balice-Gordon Rita J. | — | $171.7K | Dec 5, 2025 |
| Lurker Nancy | — | $161.9K | May 13, 2026 |
| Freund John Gordon | — | $143.2K | May 18, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 8, 2026 | SANTINI GINO Director | Option exercise | 8,700 | $143.5K |
| May 18, 2026 | Freund John Gordon Director | Sale | 20 | $681 |
| May 15, 2026 | Freund John Gordon Director | Option exercise | 8,700 | $143.5K |
| May 15, 2026 | Freund John Gordon Director | Sale | 4,127 | $142.5K |
| May 14, 2026 | BOHLIN GAREN G Director | Award | 8,741 | $0 |
| May 14, 2026 | Glancy Donovan Michael Director | Award | 17,482 | $0 |
| May 14, 2026 | Balice-Gordon Rita J. Director | Award | 8,741 | $0 |
| May 14, 2026 | Freund John Gordon Director | Award | 8,741 | $0 |
| May 14, 2026 | Lurker Nancy Director | Award | 8,741 | $0 |
| May 14, 2026 | Paya Carlos V Director | Award | 8,741 | $0 |
| May 14, 2026 | SANTINI GINO Director | Award | 8,741 | $0 |
| May 13, 2026 | Lurker Nancy Director | Sale | 4,500 | $161.9K |
| May 11, 2026 | BOHLIN GAREN G Director | Option exercise | 8,700 | $143.5K |
| May 11, 2026 | BOHLIN GAREN G Director | Sale | 8,700 | $323.5K |
| Mar 18, 2026 | Dieter David EVP & General Counsel | Sale 10b5-1 plan | 13,976 | $488.1K |
| Mar 17, 2026 | Dieter David EVP & General Counsel | Tax withheld | 8,840 | $315.8K |
| Mar 9, 2026 | Dieter David EVP & General Counsel | Sale 10b5-1 plan | 6,224 | $228.1K |
| Mar 3, 2026 | Dreyer Scott EVP & Chief Commercial Officer | Sale 10b5-1 plan | 46,417 | $1.87M |
| Mar 3, 2026 | Dreyer Scott EVP & Chief Commercial Officer | Sale 10b5-1 plan | 3,559 | $145.9K |
| Feb 10, 2026 | Smith Thomas B EVP and Chief Medical Officer | Tax withheld | 11,538 | $539.4K |
| Feb 10, 2026 | Smith Thomas B EVP and Chief Medical Officer | Tax withheld | 5,897 | $275.7K |
| Feb 10, 2026 | Smith Thomas B EVP and Chief Medical Officer | Award | 22,774 | $0 |
| Feb 10, 2026 | Dreyer Scott EVP & Chief Commercial Officer | Tax withheld | 21,615 | $1.01M |
| Feb 10, 2026 | Dreyer Scott EVP & Chief Commercial Officer | Award | 30,702 | $0 |
| Feb 10, 2026 | Dreyer Scott EVP & Chief Commercial Officer | Tax withheld | 9,977 | $466.4K |
| Feb 10, 2026 | Smith Thomas B EVP and Chief Medical Officer | Award | 14,268 | $0 |
| Feb 10, 2026 | Dreyer Scott EVP & Chief Commercial Officer | Award | 19,023 | $0 |
| Feb 10, 2026 | Karnani Vikram President and CEO | Tax withheld | 11,296 | $528.1K |
| Feb 10, 2026 | Tupper Colleen EVP & Chief Financial Officer | Award | 32,734 | $0 |
| Feb 10, 2026 | Tupper Colleen EVP & Chief Financial Officer | Award | 26,421 | $0 |
| Feb 10, 2026 | Dieter David EVP & General Counsel | Tax withheld | 2,781 | $130.0K |
| Feb 10, 2026 | Karnani Vikram President and CEO | Award | 32,531 | $0 |
| Feb 10, 2026 | Dieter David EVP & General Counsel | Award | 22,194 | $0 |
| Feb 10, 2026 | Tupper Colleen EVP & Chief Financial Officer | Tax withheld | 26,679 | $1.25M |
| Feb 10, 2026 | Tupper Colleen EVP & Chief Financial Officer | Tax withheld | 11,861 | $554.5K |
| Feb 10, 2026 | Karnani Vikram President and CEO | Award | 79,264 | $0 |
| Feb 10, 2026 | Dieter David EVP & General Counsel | Award | 9,005 | $0 |
| Dec 8, 2025 | Dreyer Scott EVP & Chief Commercial Officer | Sale 10b5-1 plan | 11,125 | $532.8K |
| Dec 8, 2025 | Dreyer Scott EVP & Chief Commercial Officer | Option exercise 10b5-1 plan | 17,600 | $279.8K |
| Dec 8, 2025 | Dreyer Scott EVP & Chief Commercial Officer | Sale 10b5-1 plan | 6,475 | $315.1K |
| Dec 5, 2025 | Balice-Gordon Rita J. Director | Sale | 3,650 | $171.7K |
| Nov 12, 2025 | Karnani Vikram President and CEO | Tax withheld | 8,983 | $425.3K |
| Nov 12, 2025 | Fallon John A. Director | Sale | 34,853 | $1.65M |
| Nov 12, 2025 | Fallon John A. Director | Option exercise | 19,853 | $185.2K |
| Nov 12, 2025 | Fallon John A. Director | Option exercise | 15,000 | $247.3K |
| Nov 6, 2025 | Tupper Colleen EVP & Chief Financial Officer | Sale 10b5-1 plan | 25,142 | $1.02M |
| Nov 6, 2025 | Tupper Colleen EVP & Chief Financial Officer | Sale 10b5-1 plan | 4,858 | $200.5K |
| Aug 29, 2025 | Smith Thomas B EVP and Chief Medical Officer | Sale | 17,478 | $671.6K |
| Aug 18, 2025 | Dreyer Scott EVP & Chief Commercial Officer | Sale 10b5-1 plan | 16,389 | $626.2K |
| Aug 18, 2025 | Dreyer Scott EVP & Chief Commercial Officer | Option exercise 10b5-1 plan | 16,389 | $349.7K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for COLLEGIUM PHARMACEUTICAL, INC
Free account. Everything above stays public.
Write why you follow COLLEGIUM PHARMACEUTICAL, INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading